Pacira BioSciences Inc. (PCRX)
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pacira BioSciences: Exparel Still Supports My Original Bull Case
PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That's why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX's overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others.
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
Pacira BioSciences, Inc. ( PCRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Mesco - Head of Investor Relations Frank Lee - CEO & Director Brendan Teehan - Chief Commercial Officer Shawn Cross - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Dennis Ding John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Pacira BioSciences Third Quarter Earnings Conference Call.
Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Jonathan Slonin - Chief Medical Officer Shawn Cross - Chief Financial Officer Brendan Teehan - Chief Commercial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Serge Belanger - Needham Operator Good day, and thank you for standing by. Welcome to the First Quarter 2025 Pacira BioSciences Earnings Conference Call.
Pacira (PCRX) Q1 Earnings Surpass Estimates
Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago.
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
